<DOC>
	<DOCNO>NCT01908660</DOCNO>
	<brief_summary>The purpose study compare liver toxicity HIV-infected patient chronic hepatitis B and/or hepatitis C , start new antiretroviral drug regimen , well influence degree pre-existing liver fibrosis incidence liver toxicity .</brief_summary>
	<brief_title>Hepatic Safety Currently Used Antiretroviral Regimens Patients With Chronic Hepatitis Under Real Life Conditions</brief_title>
	<detailed_description>In last year , various clinical trial study evaluate incidence hepatic toxicity ( HT ) associate commonly use antiretroviral drug HIV/hepatitis C virus ( HCV ) -infected population . Unfortunately , clinical trial compare hepatic safety antiretrovirals include low number coinfected patient ( van Leth 2004 , Molina 2010 , Ortiz 2008 , Rockstroh 2012 ) . According recent cohort study , rate grade 3 4 transaminase elevation ( TE ) observe patient receive ritonavir-boosted protease inhibitor PI/r lopinavir ( LPV/r ) , atazanavir ( ATV/r ) , fosamprenavir ( FPV/r ) darunavir ( DRV/r ) similar observe individual receive efavirenz ( EFV ) raltegravir ( RAL ) ( Pineda 2008 , Palacios 2006 , Macías 2011 , Neukam 2011 ) . However , conclusion may exact due methodological problem . In context , currently available data severe TE derive cohort study conduct different population , distinct method and/or data collect retrospectively . Little information available whether stage liver damage influence incidence HT cause antiretroviral drug . Although two study find association advance fibrosis high rate TE ( Aranzabal 2005 , Mira 2006 ) , data obtain study contradictory ( Pineda 2008 , Palacios 2006 , Macías 2011 , Neukam 2011 ) still open question . Thus , number cirrhotic patient considerably small cohort , however , cirrhosis represent important comorbidity HIV . In individual , plasmatic concentration antiretroviral drug could reach toxic level would reflect TE ( Barreiro 2007 ) . Therefore , study conduct population methodology require order obtain precise reliable information hepatic safety commonly use antiretroviral drug clinical practice . These finding could contribute good understanding difference antiretrovirals could therefore improve individualization antiretroviral therapy individual chronic hepatitis B and/or C. Therefore , HEPAVIR group Andalusian Society Infectious Diseases ( SAEI ) establish prospective cohort : The HEPAVIR Cohort . Hypothesis : The incidence severe TE associate antiretroviral therapy clinical practice hepatitis B virus and/or hepatitis C virus-coinfected patient could different accord administer drug . Primary objective : To determine incidence grade 3 4 TE associate antiretroviral therapy clinical practice patient viral hepatitis . Secondary objective : - Identification factor associate grade 3 4 TE - Analysis association TE pre-existing hepatic damage - Evaluate incidence serious symptom , include hepatic decompensations , acute fulminant hepatitis death due liver failure , associate antiretroviral drug - Determination incidence grade 3 4 bilirubin elevation associate antiretroviral drug - Evaluation efficacy antiretroviral drug use study Scheduled visit : 0 , 4 , 12 , 24 , 36 48 week . Definition grade 3 4 laboratory abnormalities/data dictionary : Grade 3 transaminase elevation ( TE ) consider elevation 5 10 time upper level normality ( ULN ) present patient normal baseline level alanine-aminotransferase ( ALT ) aspartate-aminotransferase ( AST ) . Grade 4 TE define ALT AST value &gt; 10 time ULN . In patient elevated baseline ALT AST level , 3.5- 5-fold increase baseline level consider grade 3 TE &gt; 5-fold elevation grade 4 TE , respectively . Grade 4 total bilirubin elevation define increase total bilirubin ≥5 mg/dl . Definition hepatic fibrosis : - advanced fibrosis : F3 determine liver biopsy 11 kilopascals determine transient elastometry - cirrhosis : F4 determine liver biopsy 14.6 kilopascals determine transient elastometry Variables collect within cohort : - primary outcome variable : AST , ALT - epidemiological variable : age , sex - variable relate hepatitis C virus-infection : infection route , genotype , grade hepatic fibrosis method use determination , baseline Child-Pough-Index , previous hepatic decompensations - variable relate HIV-infection : Centers Disease Control Prevention ( CDC ) category , HIV viral load , cluster differentiation 4 ( CD4 ) cell count , previous new antiretroviral drug - analytical variable : platelet , cholesterol , bilirubin , gamma-glutamyltransferase ( GGT ) , alkaline phosphatase - clinical variable : alcohol intake - time TE - percentage patient discontinue antiviral therapy due TE Quality assurance data check : Data obtain controlled database participate center . Databases monitor controlled query every six month . Descriptive statistic apply order detect transcription error . Source data verification : plan . All grade 3 4 adverse event , well unexpected event , report Andalusian Center Pharmacovigilance ( Centro Andaluz de Farmacovigilancia , www.cafv.es ) . A sample size 500 plan study . Statistical analysis : The outcome variable study development grade 3 4 transaminase elevation ( TE ) grade 4 total bilirubin elevation ( TBE ) follow-up . Comparative analysis TE TBE carry different drug group . Additionally , relationship outcome variable follow potential predictor assess : age , sex , previous intravenous drug use , alcohol consumption , baseline ALT level , baseline CD4 cell count , CDC category C , undetectable plasma HIV-RNA , HCV genotype , previous ART , type drug , well significant fibrosis cirrhosis initiation new ART regimen . Continuous variable express median [ interquartile range ( IQR ) ] categorical variable number [ percentage ; 95 % confidence interval ( CI ) ] . The density incidence grade 3-4 TE calculate number case per 100 person-years follow-up . Continuous variable compare use Student 's t-test normal distribution Mann-Whitney U-test otherwise , whereas categorical variable analyze apply χ2-test Fisher 's test , applicable . The Wilcoxon Signed Rank test McNemar test apply compare repeat measurement continuous categorical variable , respectively . Those factor show association univariate analysis p &lt; 0.2 , well biologically possible influence , enter logistic regression model order identify independent risk factor grade 3-4 TE grade 4 TBE . The adjusted odds ratio ( AOR ) respective 95 % CI calculate . All p value &lt; 0.05 consider statistically significant . Data analyse use SPSS statistical software package release 19.0 ( SPSS Inc. , Chicago , IL , USA ) STATA 9.0 ( StataCorp LP , College Station , TX , USA ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Older 18 year HIV1 infection confirm ELISA western blot Chronic HCV infection confirm HCV antibody plasma , well positive HCV viral load determine polymerase chain reaction OR chronic hepatitis B infection confirm HBsAg Treatmentnaive pretreated patient start new antiretroviral regimen include least one drug receive patient At least one week exposure new regimen Liver biopsy transient elastometry determination within 12 month prior treatment initiation Pregnancy Treatment hepatitis C virus infection Presence opportunistic infection , include tuberculosis , neoplasia , autoimmune disease . Patients receive primary secondary chemotherapy opportunistic process include . Any liver disease vascular , metabolic , biliary , autoimmune tumoral origin Patients able provide write informed consent participate study Lack schedule clinical visit include blood analysis throughout study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>hepatitis C virus</keyword>
	<keyword>hepatitis B virus</keyword>
	<keyword>antiretroviral drug</keyword>
	<keyword>nucleos ( ) ide reverse transcriptase inhibitor</keyword>
	<keyword>non-nucleos ( ) ide reverse transcriptase inhibitor</keyword>
	<keyword>protease inhibitor</keyword>
	<keyword>integrase inhibitor</keyword>
	<keyword>entry inhibitor</keyword>
	<keyword>transaminase elevation</keyword>
	<keyword>alanine aminotransferase</keyword>
	<keyword>aspartate aminotransferase</keyword>
	<keyword>bilirubin elevation</keyword>
	<keyword>hepatic fibrosis</keyword>
</DOC>